Paper Details

  1. Home
  2. Paper Details

Treatment of Erythrodermic Psoriasis in Children with Secukinumab: A Case Report.

Author: LuXujun, WangWenge

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.

Overview

Secukinumab, a drug previously shown to be effective in treating plaque psoriasis, was effective in treating a 7-year-old patient with erythrodermic psoriasis (EP). The patient saw significant improvement within 48 hours of the first injection and achieved almost complete clearance of skin lesions after five injections.
Paper Details　
Original Abstract of the Article :
Erythrodermic psoriasis (EP) is a rare and severe type of psoriasis. Common systemic therapies for children with EP include treatment with glucocorticoids, cyclosporine, acitretin, and methotrexate. Although these drugs are effective, they may cause serious side effects to children. Secukinumab has ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10395748/

データ提供：米国国立医学図書館（NLM）

Secukinumab: A Potential Treatment for Erythrodermic Psoriasis in Children

The field of dermatology focuses on the diagnosis and treatment of skin conditions, including psoriasis. Erythrodermic psoriasis (EP) is a rare and severe form of psoriasis that affects the entire body. This study presents a case report of a seven-year-old child with EP who was successfully treated with secukinumab, a biologic medication. The findings suggest that secukinumab may be a promising treatment option for children with EP, particularly those who have not responded well to traditional therapies.

Secukinumab: A New Hope for Children with EP

This case report provides encouraging evidence that secukinumab can effectively treat EP in children. The patient in this study showed significant improvement in their skin lesions after receiving secukinumab, with minimal side effects. While further research is needed to confirm these findings, this study suggests that secukinumab may be a valuable addition to the treatment armamentarium for children with EP.

Navigating Psoriasis: A Journey of Understanding and Management

Psoriasis is a chronic skin condition that can have a significant impact on an individual's quality of life. It's important to seek prompt medical attention for psoriasis and to work closely with a dermatologist to develop an individualized treatment plan.

Dr. Camel's Conclusion

This case report is like a glimmer of hope in the vast desert of psoriasis treatments. The findings suggest that secukinumab may offer a new path for treating EP in children. The study underscores the importance of ongoing research in this area to find effective and safe treatment options for patients with psoriasis.

Date :
  1. Date Completed n.d.
  2. Date Revised 2023-08-05
Further Info :

Pubmed ID

37539023

DOI: Digital Object Identifier

PMC10395748

Related Literature

Article Analysis
・Side Effects of secukinumab injection
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.